BioPorto has entered into an agreement with Abbott to cross-license their respective NGAL intellectual property rights (IPR). The parties have signed non-exclusive agreements, which cover all the NGAL related IPR directly and indirectly controlled by both parties – including sub-licenses from Phadia and Cincinnati Children’s Hospital.
Help employers find you! Check out all the jobs and post your resume.